Study shows early benefits of SGLT2 inhibitors in patients with heart failure

After 1 year of treatment, SGLT2 inhibitors were associated with a 32% lower risk for hospitalization due to heart failure, regardless of type 2 diabetes status, according to a new study in Annals of Internal Medicine.
Previous randomized controlled trials have established SGLT2 inhibitors as an important treatment option in patients with heart failure (HF). The class benefits extend to patients with and without diabetes.
Sheyu Li, MD, an associate professor in the department of endocrinology and metabolism at MAGIC China Center, West China Hospital and Sichuan University, and colleagues

After 1 year of treatment, SGLT2 inhibitors were associated with a 32% lower risk for hospitalization due to heart failure, regardless of type 2 diabetes status, according to a new study in Annals of Internal Medicine.
Previous randomized controlled trials have established SGLT2 inhibitors as an important treatment option in patients with heart failure (HF). The class benefits extend to patients with and without diabetes.
Sheyu Li, MD, an associate professor in the department of endocrinology and metabolism at MAGIC China Center, West China Hospital and Sichuan University, and colleagues